Balyasny Asset Management
SCMP

Balyasny Asset Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Balyasny Asset Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13,173
Closed -$178K – 1885
2016
Q4 		$178K Sell
13,173
-6,996
-35% -$97.6K ﹤0.01% 1291
2016
Q3 		$248K Sell
20,169
-4,274
-17% -$50.4K ﹤0.01% 848
2016
Q2 		$268K Buy
24,443
+9,474
+63% +$106K ﹤0.01% 952
2016
Q1 		$164K Buy
+14,969
New +$189K ﹤0.01% 1152

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's SCMP Position: Q1 2017 in Review

Balyasny Asset Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2017, closing a stake of 13,173 shares — an estimated $178K sold.

Balyasny Asset Management first reported a position in SCMP in Q1 2016 and held it in 4 quarters. The position peaked at $268K in Q2 2016. 167 funds tracked by Wall St. Rank hold SCMP as of Q1 2017.

  • Balyasny Asset Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Balyasny Asset Management sold 13,173 Sucampo Pharmaceuticals, Inc. shares in Q1 2017, an estimated $178K.
  • Balyasny Asset Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2016 and held it in 4 quarters.
  • Balyasny Asset Management's Sucampo Pharmaceuticals, Inc. position peaked at $268K in Q2 2016.
  • 167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2017.

Based on Balyasny Asset Management's 13F filing for Q1 2017, filed 15 May 2017.